摘要
目的探索应用含氯法齐明联合方案治疗耐多药结核病患者的应用效果。方法选取2018年1月至2019年2月徐州市丰县人民医院收治的54例耐多药结核病患者作为研究对象,按照随机数字表法分为对照组与观察组,每组27例。对照组患者给予卷曲霉素、丙硫异烟肼、吡嗪酰胺、左氧氟沙星、对氨基水杨酸钠治疗,观察组患者在此基础上应用氯法齐明治疗,对比两组患者的治疗总有效率、痰菌阴转率、不良反应发生率。结果治疗6个月、12个月、18个月后,观察组的痰菌阴转率均低于对照组,差异有统计学意义(P<0.05);治疗6个月后,观察组的总有效率为66.67%,高于对照组的总有效率37.04%,差异有统计学意义(P<0.05);治疗18个月后,观察组的总有效率高于对照组的总有效率(92.59%vs.70.37%),差异有统计学意义(P<0.05);两组的不良反应发生率比较,差异无统计学意义(P>0.05)。结论含氯法齐明的抗结核治疗方案在耐多药肺结核患者的治疗中应用疗效肯定,有助于促进结核分枝杆菌的清除,促进病灶吸收,且用药安全性高。
Objective To explore the application effect of combined regimen containing clofazimine in patients with MDR-TB.Methods A total of 54 cases of MDR-TB patients treated in Xuzhou Fengxian People's Hospital from January 2018 to February 2019 were selected and randomly divided into control group and observation group with 27 cases in each group.The control group was treated with capreomycin,propionate isoniazid,pyrazinamide,levofloxacin and sodium p-aminosalicylate,while the observation group was treated with clofazimine on this basis.The total effective rate,sputum negative conversion rate and incidence of adverse reactions were compared between the two groups.Results After 6 months,12 months and 18 months of treatment,the sputum negative conversion rate of the observation group was lower than that of the control group,the difference was statistically significant(P<0.05);after 6 months of treatment,the total effective rate of the observation group was 66.67%,higher than that of the control group 37.04%,the difference was statistically significant(P<0.05);after 18 months of treatment,the total effective rate of the observation group was higher than that of the control group(92.59%vs.70.37%),the difference was statistically significant(P<0.05);there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The efficacy of anti tuberculosis treatment with clofazimine in the treatment of MDR-TB patients is positive,which is helpful to promote the elimination of Mycobacterium tuberculosis,promote the absorption of lesions,and has high drug safety.
作者
张翔
ZHANG Xiang(Xuzhou Fengxian People's Hospital,Xuzhou,Jiangsu 221700,China)
出处
《大医生》
2020年第13期80-82,共3页
Doctor
